Abstract
Background Neurofibromatosis Type 1 (NF1) is a genetic neurodevelopmental disorder commonly associated with impaired cognitive function. Despite the well-explored functional roles of neural oscillations in neurotypical populations, only a limited number of studies have investigated oscillatory activity in the NF1 population.
Methods We compared oscillatory spectral power and theta phase coherence in a paediatric sample with NF1 (N=16; mean age: 13.03 years; female: n=7) to an age/sex-matched typically-developing control group (N=16; mean age: 13.34 years; female: n=7) using electroencephalography measured during rest and during working memory task performance.
Results Relative to typically-developing children, the NF1 group displayed higher resting state slow wave power and a lower peak alpha frequency. Moreover, higher theta power and frontoparietal theta phase coherence were observed in the NF1 group during working memory task performance, but these differences disappeared when controlling for baseline (resting state) activity.
Conclusions Overall, results suggest that NF1 is characterised by aberrant resting state oscillatory activity that may contribute towards the cognitive impairments experienced in this population.
Trial registration ClinicalTrials.gov identifier: NCT03310996 (first posted: October 16 2017).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Data collection was funded by the Newlife Charity for Disabled Children. The analysis and write-up was conducted as part of a PhD funded by the Economic and Social Research Council (ESRC), awarded to Miss Samantha Booth. The funders had no role in the study design, data collection, data analysis, statistical analysis, interpretation of the data, writing of the paper, or decision regarding when to submit the publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received ethical approval from the Greater Manchester West Research Ethics Committee (17/NW/0364) and was conducted in accordance with the Declaration of Helsinki. Trial registration: ClinicalTrials.gov identifier: NCT03310996 (first posted: October 16 2017). Parents/guardians gave oral and written consent, and adolescents assent (where developmentally appropriate), prior to participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses: samantha.booth{at}manchester.ac.uk, shruti.garg{at}manchester.ac.uk, laura.brown{at}manchester.ac.uk, jonathan.green{at}manchester.ac.uk, gorana.pobric{at}manchester.ac.uk, and jason.taylor{at}manchester.ac.uk
5 For task-related data, the number of trials remaining reflects the number of trials after incorrect responses were removed.
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
6. Abbreviations
- ADHD
- Attention-deficit hyperactivity disorder
- ASD
- Autism spectrum disorder
- CON
- Control
- EEG
- Electroencephalography
- ERP
- Event-Related Potential
- fMRI
- Functional Magnetic Resonance Imaging
- ICA
- Independent Components Analysis
- IQ
- Intelligence Quotient
- ISPC
- Inter-site phase clustering
- M
- Mean
- ML
- Mid-frontal – left-parietal
- MM
- Mid-frontal – mid-parietal
- MR
- Mid-frontal – right-parietal
- NF1
- Neurofibromatosis Type 1
- PAF
- Peak alpha frequency
- SD
- Standard deviation
- VABS-II
- Vineland Adaptive Behaviour Scale
- Vineland ABC
- Vineland Adaptive Behaviour Composite
